Treatment of dyslipidaemia in childhood

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 739-753

  Kusters, D Meeike ^a   Vissers, Maud N ^a   Wiegman, Albert ^a   Kastelein, John J P ^a   Hutten, Barbara A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Children; Dyslipidaemia; Lifestyle modification; Lipid lowering medication; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID BINDING RESIN; CIPROFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; APHERESIS; ATHEROSCLEROSIS; AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHILDHOOD; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIET THERAPY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EARLY DIAGNOSIS; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LECITHIN CHOLESTERYL ACYLTRANSFERASE DEFICIENCY; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER TOXICITY; METABOLIC SYNDROME X; MYOPATHY; NEPHROTIC SYNDROME; OBESITY; ORGAN TRANSPLANTATION; OVARY POLYCYSTIC DISEASE; PATIENT COUNSELING; PHYSICAL ACTIVITY; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SITOSTEROLEMIA; SMOKING CESSATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TANGIER DISEASE; WEIGHT CONTROL;

ADOLESCENT; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; INFANT; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 77949430896     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003592169     Document Type: Review

References (123)

1. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198-208
2. National Cholesterol Education Program (NCEP). Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:495-501
3. Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005;112:2061-2075
4. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 2001;107:256-264
5. Rask-Nissila L, Jokinen E, Terho P, et al. Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy: a randomized controlled trial. JAMA 2000;284:993-1000
6. Kaitosaari T, Ronnemaa T, Raitakari O, et al. Effect of 7-year infancy-onset dietary intervention on serum lipoproteins and lipoprotein subclasses in healthy children in the prospective, randomized Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. Circulation 2003;108:672-677
7. Friedman G, Goldberg SJ. An evaluation of the safety of a low-saturated-fat, low-cholesterol diet beginning in infancy. Pediatrics 1976;58:655-657
8. Ballew C, Kuester S, Serdula M, et al. Nutrient intakes and dietary patterns of young children by dietary fat intakes. J Pediatr 2000;136:181-187
9. Nicklas TA, Webber LS, Koschak M, et al. Nutrient adequacy of low fat intakes for children: the Bogalusa Heart Study. Pediatrics 1992;89:221-228
10. Shea S, Basch CE, Stein AD, et al. Is there a relationship between dietary fat and stature or growth in children three to five years of age? Pediatrics 1993;92:579-586
11. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation 2007;116:1032-1040
12. Tershakovec AM, Jawad AF, Stallings VA, et al. Growth of hypercholesterolemic children completing physician-initiated low-fat dietary intervention. J Pediatr 1998;133:28-34
13. Van Horn L, McCoin M, Kris-Etherton PM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 2008;108:287-331
14. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res 1995;36:1807-1812
15. Amundsen AL, Ose L, Nenseter MS, et al. Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 2002;76:338-344
16. Tammi A, Ronnemaa T, Miettinen TA, et al. Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters in children: the STRIP study. Special Turku Coronary Risk Factor Intervention Project. Acta Paediatr 2002;91:1155-1162
17. Kwiterovich PO Jr. The role of fiber in the treatment of hypercholesterolemia in children and adolescents. Pediatrics 1995;96:1005-1009
18. Davidson MH, Dugan LD, Burns JH, et al. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr 1996;63:96-102
19. Jacques H, Laurin D, Moorjani S, et al. Influence of diets containing cow's milk or soy protein beverage on plasma lipids in children with familial hypercholesterolemia. J Am Coll Nutr 1992;11(Suppl):69-73
20. Weghuber D, Widhalm K. Effect of 3-month treatment of children and adolescents with familial and polygenic hypercholesterolaemia with a soya-substituted diet. Br J Nutr 2008;99:281-286
21. Engler MM, Engler MB, Malloy MJ, et al. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 2005;95:869-871
22. Kelley GA, Kelley KS. Effects of aerobic exercise on non-high-density lipoprotein cholesterol in children and adolescents: a meta-analysis of randomized controlled trials. Prog Cardiovasc Nurs 2008;23:128-132
23. Strong WB, Malina RM, Blimkie CJ, et al. Evidence based physical activity for school-age youth. J Pediatr 2005;146:732-737
24. Kokkinos P. Physical activity and cardiovascular disease prevention: current recommendations. Angiology 2008;59(Suppl):26-29
25. Dobbins M, De CK, Robeson P, et al. School-based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6-18. Cochrane Database Syst Rev 2009:CD007651
26. Swain DP, Franklin BA. Comparison of cardioprotective benefits of vigorous versus moderate intensity aerobic exercise. Am J Cardiol 2006;97:141-147
27. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256:482-490
28. Alonso R, Mata N, Castillo S, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008;200:315-321
29. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009;205:23-32
30. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582
31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
32. Lahera V, Goicoechea M, de Vinuesa SG, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007;14:243-248
33. Avis HJ, Vissers MN, Wijburg FA, et al. The use of lipid-lowering drug therapy in children and adolescents. Curr Opin Investig Drugs 2009;10:224-231
34. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007;27:1803-1810
35. Lutjohann D, von Bergmann K, Sirah W, et al. Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J Clin Pract 2008;62:1499-1510
36. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52:1421-1429
37. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
38. Shepherd J, Packard CJ, Bicker S, et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302:1219-1222
39. Robinson DM, Keating GM. Colesevelam: a review of its use in hypercholesterolemia. Am J Cardiovasc Drugs 2007;7:453-465
40. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-1967
41. Defesche JC. Familial hypercholesterolaemia. In: Betteridge DJ, editor, Lipids and Vascular Disease; 2000. p. 65-76
42. Ueland T, Vissers MN, Wiegman A, et al. Increased inflammatory markers in children with familial hypercholesterolaemia. Eur J Clin Invest 2006;36:147-152
43. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117-2121
44. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004;363:369-370
45. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292:331-337
46. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116:664-668
47. Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009;154:869-872
48. Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009;22:487-492
49. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors, The metabolic & molecular bases of inherited disease. 8th edition; 2001. p. 2863-2913
50. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004;15:413-422
51. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-255
52. Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973;52:1533-1543
53. Iwata F, Okada T, Kuromori Y, et al. Screening for familial combined hyperlipidemia in children using lipid phenotypes. J Atheroscler Thromb 2003;10:299-303
54. Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial combined hyperlipidemia in childhood. J Pediatr 1990;116:514-519
55. Shamir R, Tershakovec AM, Gallagher PR, et al. The influence of age and relative weight on the presentation of familial combined hyperlipidemia in childhood. Atherosclerosis 1996;121:85-91
56. Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002;90:30i-47i
57. Pauciullo P, Gentile M, Marotta G, et al. Small dense low-density lipoprotein in familial combined hyperlipidemia: independent of metabolic syndrome and related to history of cardiovascular events. Atherosclerosis 2009;203:320-324
58. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003;92:27J-33J
59. de Graaf A, van der Vleuten G, Stalenhoef AF. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 2004;4:229-240
60. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2003;23:1963-1970
61. Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002;359:841-847
62. Naoumova RP, Neuwirth C, Lee P, et al. Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. Atherosclerosis 2004;174:165-172
63. Lind S, Olsson AG, Eriksson M, et al. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 2004;256:406-412
64. Beigneux AP, Franssen R, Bensadoun A, et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol 2009;29:956-962
65. Feoli-Fonseca JC, Levy E, Godard M, et al. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. J Pediatr 1998;133:417-423
66. Brunzell JD, Deeb SS. Deficiencies of lipoprotein lipase, apo C-II, and hepatic lipase. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors, The metabolic & molecular bases of inherited disease. 8th edition; 2001. p. 2789-2816
67. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008;28:2303-2304
68. Salen G, von Bergmann K, Lutjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109:966-971
69. Wang J, Joy T, Mymin D, et al. Phenotypic heterogeneity of sitosterolemia. J Lipid Res 2004;45:2361-2367
70. Salen G, Starc T, Sisk CM, et al. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006;130:1853-1857
71. Assmann G, von Eckardstein A, Brewer HB Jr. Familial analphalipoproteinemia: tangier disease. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors, The metabolic & molecular bases of inherited disease. 8th edition; 2001. p. 2937-2960
72. Hovingh GK, de Groot E, van der Steeg W, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005;16:139-145
73. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr Diabetes 2007;8:299-306
74. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000;136:664-672
75. Freedman DS, Dietz WH, Srinivasan SR, et al. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999;103:1175-1182
76. Ssimacopoulos-Jeannet F, Brichard S, Rencurel F, et al. In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues. Metabolism 1995;44:228-233
77. Kelly AS, Steinberger J, Kaiser DR, et al. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr 2006;1:248-252
78. Aeberli I, Molinari L, Spinas G, et al. Dietary intakes of fat and antioxidant vitamins are predictors of subclinical inflammation in overweight Swiss children. Am J Clin Nutr 2006;84:748-755
79. Meyer AA, Kundt G, Steiner M, et al. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics 2006;117:1560-1567
80. Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001;358:1400-1404
81. Roh EJ, Lim JW, Ko KO, et al. A useful predictor of early atherosclerosis in obese children: serum high-sensitivity C-reactive protein. J Korean Med Sci 2007;22:192-197
82. Litwin M, Niemirska A. Intima-media thickness measurements in children with cardiovascular risk factors. Pediatr Nephrol 2009;24:707-719
83. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-1656
84. Janssen I, Katzmarzyk PT, Srinivasan SR, et al. Utility of childhood BMI in the prediction of adulthood disease: comparison of national and international references. Obes Res 2005;13:1106-1115
85. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007;357:2329-2337
86. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003;290:2277-2283
87. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003;290:2271-2276
88. Knip M, Nuutinen O. Long-term effects of weight reduction on serum lipids and plasma insulin in obese children. Am J Clin Nutr 1993;57:490-493
89. Epstein LH, Kuller LH, Wing RR, et al. The effect of weight control on lipid changes in obese children. Am J Dis Child 1989;143:454-457
90. Kirk S, Zeller M, Claytor R, et al. The relationship of health outcomes to improvement in BMI in children and adolescents. Obes Res 2005;13:876-882
91. Reinehr T, de Sousa G, Toschke AM, et al. Long-term follow-up of cardiovascular disease risk factors in children after an obesity intervention. Am J Clin Nutr 2006;84:490-496
92. Reinehr T, Kleber M, Toschke AM. Lifestyle intervention in obese children is associated with a decrease of the metabolic syndrome prevalence. Atherosclerosis 2009
93. Ford ES, Li C, Zhao G, et al. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation 2009;119:1108-1115
94. Bell RA, Mayer-Davis EJ, Beyer JW, et al. Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009;32(Suppl 2):102-111
95. Bloomgarden ZT. American Diabetes Association annual meeting, 1999: dyslipidemia, endothelial dysfunction, and glycosylation. Diabetes Care 2000;23:690-698
96. Mautner SL, Lin F, Roberts WC. Composition of atherosclerotic plaques in the epicardial coronary arteries in juvenile (type I) diabetes mellitus. Am J Cardiol 1992;70:1264-1268
97. Schwab KO, Doerfer J, Hecker W, et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006;29:218-225
98. Marcovecchio ML, Dalton RN, Prevost AT, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 2009;32:658-663
99. Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care 2009;32:416-420
100. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000;26:254-264
101. Jarvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004;109:1750-1755
102. Heilman K, Zilmer M, Zilmer K, et al. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pract 2009;84:168-173
103. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-2738
104. Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005;28:186-212
105. Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:65-68
106. Thabet MA, Salcedo JR, Chan JC. Hyperlipidemia in childhood nephrotic syndrome. Pediatr Nephrol 1993;7:559-566
107. Hu P, Lu L, Hu B, et al. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Scand J Clin Lab Invest 2009:1-7
108. Prescott WA Jr, Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004;38:2105-2114
109. Hopp L, Gilboa N, Kurland G, et al. Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature. Pediatr Nephrol 1994;8:290-294
110. D'Amico G, Gentile MG, Manna G, et al. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 1992;339:1131-1134
111. Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997;130:470-474
112. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996;10:171-174
113. Rayner BL, Byrne MJ, van Zyl SR. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 1996;46:219-224
114. Harwood K, Vuguin P, Martino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 2007;68:209-217
115. Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2740-2746
116. Shroff R, Kerchner A, Maifeld M, et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007;92:4609-4614
117. Westerveld HE, Hoogendoorn M, de Jong AW, et al. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Ther 2008;119:223-241
118. El-Sabrout R, Weiss R, Butt F, et al. Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. Transplant Proc 2002;34:1946-1947
119. Chin C, Rosenthal D, Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000;4:193-199
120. Law YM, Yim R, Agatisa P, et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 2006;25:276-282
121. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002;110:e56
122. Rumbo C, Betzhold J, Merati S, et al. Autoimmune hyperlipidemia in a child with autoimmune hepatitis. J Clin Gastroenterol 2002;35:196-199
123. Ardoin SP, Sandborg C, Schanberg LE. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007;16:618-626